Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeBetter MedSHSE:688759 -17.26%4 Forward Dividend Yield % is 0.00% as of Jul. 28, 2026. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100. Among 149 Biotechnology companies, BeBetter Med ranks worse than 671140.27% on this metric.
As of today (2026-07-28), the Forward Annual Dividend Yield of BeBetter Med is 0.00%.
As of today (2026-07-28), the Trailing Annual Dividend Yield of BeBetter Med is 0.00%.
SHSE:688759's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.35 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
BeBetter Med (SHSE:688759) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
BeBetter Med Forward Dividend Yield % Related Terms
SHSE:688759 vs VRTX, REGN, RVMD: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, BeBetter Med's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeBetter Med Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeBetter Med's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where BeBetter Med's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
BeBetter Med (SHSE:688759) has a Forward Dividend Yield % of 0.00% as of Jul. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BeBetter Med and its competitors. According to the industry distribution chart, BeBetter Med ranks #999999 out of 149 companies in the Biotechnology industry.
Is BeBetter Med's Forward Dividend Yield % too high?
BeBetter Med's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, BeBetter Med ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BeBetter Med ranks #999999 out of 149 companies for Forward Dividend Yield %. This places BeBetter Med in the lower half of its industry. The industry median Forward Dividend Yield % is 1.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.35, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BeBetter Med and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeBetter Med's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current Forward Dividend Yield % is 0.00% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score
Get the complete analysis for SHSE:688759
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688759 has been successfully added to your 
